Breaking Colombia’s Swift Earthquake Response Contrasts With Venezuela’s Troubled Relief Efforts European Agriculture Grapples With Severe Drought, Climate Change Impacts Swiss Alps Resorts Pivot Snowmaking Tech to Combat Summer Wildfires Unlocking iPhone Efficiency: Hidden Keyboard Shortcuts Revealed Southern California Beaches See Surge in Stingray Injuries Amid Marine Heat Wave

Thursday August 13, 2026

Reporter

Outlook Therapeutics, Inc.

4Articles Published

5Communities Covered

Published Articles

Press Release

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

6 hours ago

Press Release

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

11 hours ago

Press Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Aug 6

Press Release

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Jul 24